Ariadne Bio

Developing a non-hallucinogenic serotonergic therapy for apathy in Parkinson's disease.

Health Tech & Life Sciences
Active
Pre-Seed New York, United States Founded 2026
Last updated 2026-09-18
Total raised
Last: Grant 2026-09
Stage
Pre-Seed
Founded
2026
Headcount
HQ
New York, United States
Sector
Health Tech & Life Sciences

About

Ariadne Bio is a clinical-stage neuropsychiatry company focused on developing AB-300, a non-hallucinogenic serotonin 2A receptor agonist, to treat apathy in Parkinson's disease and other brain aging conditions. The company was spun out of Palomar Labs and is advancing AB-300 into a Phase 1b clinical trial with funding from The Michael J. Fox Foundation for Parkinson's Research.

Funding history · 1 round · — total

1 event/round · Total Funding
Sep 2026
Grant Undisclosed businesswire.com ↗

Offices

New York, United States · HQ / main office

Q&A

What is Ariadne Bio's primary focus?
Ariadne Bio is a clinical-stage neuropsychiatry company focused on developing AB-300, a non-hallucinogenic serotonin 2A receptor agonist, to treat apathy in Parkinson's disease and other brain aging conditions.
When was Ariadne Bio founded?
Ariadne Bio was founded in September 2026.
What is the current stage of Ariadne Bio?
Ariadne Bio is currently in the Pre-Seed stage.
Which organization provided a grant to Ariadne Bio?
In September 2026, Ariadne Bio received a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).
What is the name of Ariadne Bio's lead therapeutic candidate?
Ariadne Bio's lead therapeutic candidate is AB-300.
What is the planned clinical trial for AB-300?
Ariadne Bio is advancing AB-300 into a Phase 1b clinical trial.
Who is the Founder and CEO of Ariadne Bio?
Shlomi Raz is the Founder and Chief Executive Officer of Ariadne Bio.
Where is Ariadne Bio headquartered?
Ariadne Bio is headquartered in New York, United States.

Team · 4

Shlomi Raz
Founder · Founder and Chief Executive Officer
Shlomi Raz
Founder and Chief Executive Officer
Kostia Adamsky
Chief Operating Officer
Daniel E. Jeffries
Chief Development Officer

Sectors & technology

Primary sector
Health Tech & Life Sciences
Technologies
Target customers

Tags

biotechnologyneuropsychiatryparkinson's-diseasedrug-developmentclinical-stage
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)